Endocrine Abstracts

Subclinical hypothyroidism (SCH), defined as a state of elevated TSH concentrations in the presence of normal free thyroxine and triiodothyronine concentrations, can be mild or severe according to the extent of TSH increase. The disease may be progressive or regressive, while the main cause of SCH is chronic autoimmune thyroiditis. However, treatment of SCH remains controversial, levothyroxine being the treatment of choice. It should be initiated in pregnant women and in patie...

Objective: To assess the regulation of parathormone (PTH) and serum calcium (s-Ca) in patients, on follow-up over a long time period of four years, who have primary hyperparathyroidism (pHPT) and whose condition is non-operable or who are not willing to undergo surgery.Methods: Initially, 17 patients with documented pHPT were recruited and treated with calcimimetic cinacalcet at a dose calculated according to s-Ca levels (≤11 mg/dl or >11 mg/dl...

Background: Levothyroxine (LT4-Rx) is one of the most prescribed drugs worldwide and the vast majority of patients receive long-term treatment. However, in a recent study of 291 subjects we found that 60% of this cohort were euthyroid two months after LT4-Rx discontinuation1.Aim of the study: A prospective clinical cohort follow-up study was carried out. In 688 subjects (82% females) aged 48.01±15.96 (range 17-84years) with 8.59±6.98...

Background: Levothyroxine (LT4Rx) is one of the most prescribed drugs worldwide the vast majority of patients receive long-term treatment. However, in a recent study of 291 subjects, it was found that 60% were euthyroid 2 months after LT4-Rx discontinuation1.Aim of the study: A prospective clinical cohort follow-up study was carried out. In 688 subjects (82% females) aged 48.01±15.96 (range 17-84years) with 8.59±6.98 years on LT4Rx witho...

Background: Levothyroxine (LT4) is one of the most prescribed drugs worldwide. Once started, about 90% of patients continue LT4 treatment long-term.Aim of the study: To evaluate the necessity of long-term thyroxine supplementation and to determine the prognostic factors that could identify which patients may discontinue LT4 treatment.Design and methods: LT4 replacement therapy was paused for at least six weeks in all patients conse...